<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02250664</url>
  </required_header>
  <id_info>
    <org_study_id>P50DA036114:P2S2</org_study_id>
    <secondary_id>P50DA036114</secondary_id>
    <nct_id>NCT02250664</nct_id>
  </id_info>
  <brief_title>Project 2, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Opioid Abusers</brief_title>
  <acronym>P2S2</acronym>
  <official_title>Project 2, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Opioid Abusers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine extended exposure to cigarettes varying in nicotine content among&#xD;
      opioid abusers. Prevalence of smoking among opioid-dependent adults far exceeds that of the&#xD;
      general US adult population. Opioid-dependent smokers are also at elevated risk for&#xD;
      smoking-related adverse health effects. Studies testing an innovative regulatory strategy of&#xD;
      reducing the nicotine content of cigarettes to a non-addictive level have shown promising&#xD;
      beneficial effects (decreased smoking rate, reduced toxicant exposure, and increased&#xD;
      cessation) in the general population of smokers. However, these studies have uniformly&#xD;
      excluded vulnerable populations like opioid abusers who may respond differently considering&#xD;
      their greater vulnerability to smoking and nicotine dependence. Thus, little is known&#xD;
      scientifically about how this highly vulnerable subgroup of smokers might respond to a&#xD;
      nicotine reduction policy. This project is designed to address that substantial knowledge&#xD;
      gap.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">October 2019</completion_date>
  <primary_completion_date type="Actual">October 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cigarettes per day</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">282</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>0.8 mg nicotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.8 mg nicotine very low nicotine content cigarettes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.12 mg nicotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.12 mg nicotine very low nicotine content cigarettes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.03 mg nicotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.03 mg nicotine very low nicotine content cigarettes</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Very low nicotine content cigarettes</intervention_name>
    <description>Very low nicotine content cigarettes</description>
    <arm_group_label>0.03 mg nicotine</arm_group_label>
    <arm_group_label>0.12 mg nicotine</arm_group_label>
    <arm_group_label>0.8 mg nicotine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women ages 18-70, who are currently receiving methadone or buprenorphine&#xD;
             maintenance treatment for opioid dependence.&#xD;
&#xD;
          2. Report smoking â‰¥ 5 cigarettes per day.&#xD;
&#xD;
          3. Provide an intake breath CO sample &gt;8 ppm.&#xD;
&#xD;
          4. Be without current (within the past year) serious mental disorder that would interfere&#xD;
             with study results or completion as determined by the licensed medical professional or&#xD;
             PI.&#xD;
&#xD;
          5. Be sufficiently literate to complete the research-related tasks.&#xD;
&#xD;
          6. Be in good physical health without serious illness or change in health or medication&#xD;
             (not including methadone or buprenorphine dose) in the past three months as determined&#xD;
             by the license medical professional at each site.&#xD;
&#xD;
          7. Not pregnant or nursing, and report using oral, implant, injection or barrier&#xD;
             contraceptives, or report being surgically sterile, or post menopausal.&#xD;
&#xD;
          8. Report no significant use of other tobacco or nicotine products within the past month&#xD;
             (more than 9 days in the past 30).&#xD;
&#xD;
          9. Participants must be maintained on a stable methadone or buprenorphine dose for the&#xD;
             past month, with no evidence of regular illicit-drug abuse (&lt;30% positive specimens in&#xD;
             the past 30 days).&#xD;
&#xD;
               1. Consent to confirm dose and drug abstinence with the participant's opioid clinic&#xD;
                  will be obtained at screening and we will monitor any changes in dose throughout&#xD;
                  the study.&#xD;
&#xD;
               2. Participants must provide at least three urine samples within the last 30 days.&#xD;
                  If they do not have three they will be asked to come in and provide a sample.&#xD;
                  They may leave up to two samples per week with at least one full day between&#xD;
                  samples.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any prior regular use (used as primary cigarette outside of laboratory) of Spectrum&#xD;
             cigarettes (i.e., research cigarettes with reduced nicotine content).&#xD;
&#xD;
          2. Exclusive use of roll-your-own cigarettes.&#xD;
&#xD;
          3. Planning to quit smoking in the next 30 days.&#xD;
&#xD;
          4. A quit attempt in the past 30 days resulting in greater than 3 days of abstinence.&#xD;
&#xD;
          5. Currently taking anticonvulsant medications.&#xD;
&#xD;
          6. Positive toxicology screen for illicit drugs not including Marijuana ( participants&#xD;
             with valid prescriptions will not be excluded and participants with a positive&#xD;
             toxicology screen will be allowed to re-screen once).&#xD;
&#xD;
          7. Not currently enrolled in a treatment program for opioid dependence and/or not&#xD;
             currently stable on their methadone or buprenorphine dose.&#xD;
&#xD;
          8. Breath alcohol level &gt; 0.01 ( participants with a positive screen will be allowed to&#xD;
             re-screen once).&#xD;
&#xD;
          9. Self-report of binge drinking alcohol (more than 9 days in the past 30 days, 4/5&#xD;
             drinks in a 2 hour period in females/males),&#xD;
&#xD;
         10. Blood pressure is greater than or equal to 160/100 mmHg or below 90/50 mmHg&#xD;
             (participants outside the range will be allowed to re-screen once).&#xD;
&#xD;
             a. Participants failing for blood pressure will be allowed to re-screen once.&#xD;
&#xD;
         11. Breath CO &gt; 80 ppm.&#xD;
&#xD;
         12. Heart rate is greater than or equal to 115 bpm or less than 45 bpm ( participants&#xD;
             outside the range will be allowed to re-screen once).&#xD;
&#xD;
         13. Currently seeking treatment for smoking cessation.&#xD;
&#xD;
         14. Have used nicotine replacement, bupropion or other pharmacotherapies as cessation aids&#xD;
             in the past month (bupropion will be allowed for treatment of depression).&#xD;
&#xD;
         15. Current symptoms of psychosis or dementia, or mania.&#xD;
&#xD;
         16. Suicidal ideation in the past month. 17.) Suicide attempt in the past 6 months. 18.)&#xD;
             Participation in another research study in the past 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen T. Higgins, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stacey Sigmon, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>September 23, 2014</study_first_submitted>
  <study_first_submitted_qc>September 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2014</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>Stephen T. Higgins, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Biomarkers of exposure</keyword>
  <keyword>Compensatory smoking</keyword>
  <keyword>Nicotine dependence</keyword>
  <keyword>Reduced nicotine cigarettes</keyword>
  <keyword>Tobacco withdrawal</keyword>
  <keyword>Women</keyword>
  <keyword>Health disparities</keyword>
  <keyword>Vulnerable populations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

